Efgartigimod + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postural Orthostatic Tachycardia Syndrome
Conditions
Postural Orthostatic Tachycardia Syndrome
Trial Timeline
Sep 23, 2022 → Apr 18, 2024
NCT ID
NCT05633407About Efgartigimod + Placebo
Efgartigimod + Placebo is a phase 2 stage product being developed by Argenx for Postural Orthostatic Tachycardia Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05633407. Target conditions include Postural Orthostatic Tachycardia Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05817669 | Phase 2 | Completed |
| NCT05633407 | Phase 2 | Completed |
Competing Products
6 competing products in Postural Orthostatic Tachycardia Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ivabradine + Placebo | Amgen | Phase 3 | 76 |
| REGN7544 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| IgPro20 + Placebo | CSL | Phase 3 | 76 |
| Efgartigimod | Argenx | Phase 2 | 49 |
| Northera (Droxidopa) + Placebo + Northera (Droxidopa) + Placebo | Lundbeck | Phase 2 | 49 |
| IVIG + Albumin | Grifols | Phase 1/2 | 38 |